Company intelligence / Profile preview

Mediphage Bioceuticals

Toronto, Ontario, Canadamediphage.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

Mediphage’s msDNAᵀᴹ platform has demonstrated durable in vivo transgene expression with improved safety profile over traditional plasmid or viral-based systems. Preclinical studies show sustained expression after multiple doses in animal models, suggesting potential for redosable genetic medicines with lower immunogenicity risk. No clinical trial results are yet reported.

Therapeutic areas: OphthalmologyHematologyNeurology
Modalities: Non-viral gene therapyDNA vectors (ministring DNA/msDNA)Gene additionIn vivo gene editingEx vivo cell therapy starting materialmRNA, lentiviral, and rAAV vector manufacturing support
Industry: Biotech

Partnerships

JLABS accelerator at Toronto MaRS CentreIllumina AcceleratorUniversity of WaterlooCreative Destruction Lab

Beyond the preview

Go deeper on Mediphage Bioceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediphage Bioceuticals.

Explore the full profile